Lord, Abbett & Co. LLC Pfizer Inc Transaction History

Lord, Abbett & Co. LLC

$31.4 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 07, 2024	SELL	$32.09 - $37.51 $50.5 Million - $59.1 Million	-1,574,816 Reduced 63.86%	891,390 $29.6 Million
Q3 2023 Nov 13, 2023	SELL	$32.09 - $37.51 $50.5 Million - $59.1 Million	-1,574,816 Reduced 63.86%	891,390 $29.6 Million
Q2 2023 Oct 07, 2024	SELL	$36.12 - $41.79 $15.6 Million - $18.1 Million	-432,990 Reduced 14.93%	2,466,206 $90.5 Million
Q2 2023 Aug 14, 2023	SELL	$36.12 - $41.79 $15.6 Million - $18.1 Million	-432,990 Reduced 14.93%	2,466,206 $90.5 Million
Q1 2023 Oct 07, 2024	SELL	$39.39 - $51.28 $59.4 Million - $77.3 Million	-1,507,566 Reduced 34.21%	2,899,196 $118 Million
Q1 2023 May 12, 2023	SELL	$39.39 - $51.28 $59.4 Million - $77.3 Million	-1,507,566 Reduced 34.21%	2,899,196 $118 Million
Q4 2022 Oct 07, 2024	BUY	$41.75 - $54.5 $184 Million - $240 Million	4,406,762 New	4,406,762 $226 Million
Q4 2022 Feb 10, 2023	SELL	$41.75 - $54.5 $57.2 Million - $74.7 Million	-1,369,807 Reduced 23.71%	4,406,762 $226 Million
Q3 2022 Nov 14, 2022	SELL	$43.76 - $53.42 $9 Million - $11 Million	-205,621 Reduced 3.44%	5,776,569 $253 Million
Q2 2022 Aug 12, 2022	SELL	$46.53 - $55.17 $64.7 Million - $76.7 Million	-1,389,706 Reduced 18.85%	5,982,190 $314 Million
Q1 2022 May 13, 2022	BUY	$45.75 - $56.69 $22.7 Million - $28.1 Million	495,987 Added 7.21%	7,371,896 $382 Million
Q4 2021 Feb 11, 2022	BUY	$41.32 - $61.25 $212 Million - $314 Million	5,125,851 Added 292.9%	6,875,909 $406 Million
Q3 2021 Nov 09, 2021	BUY	$39.25 - $50.42 $68.7 Million - $88.2 Million	1,750,058 New	1,750,058 $75.3 Million
Q3 2020 Nov 12, 2020	SELL	$31.75 - $37.25 $28.3 Million - $33.2 Million	-890,200 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$30.12 - $36.54 $74.8 Million - $90.7 Million	-2,482,262 Reduced 73.6%	890,200 $29.1 Million
Q1 2020 May 14, 2020	SELL	$27.03 - $38.62 $4.24 Million - $6.06 Million	-156,786 Reduced 4.44%	3,372,462 $110 Million
Q4 2019 Feb 14, 2020	SELL	$32.92 - $37.36 $7.19 Million - $8.16 Million	-218,301 Reduced 5.83%	3,529,248 $138 Million
Q3 2019 Nov 14, 2019	SELL	$32.49 - $42.13 $18.2 Million - $23.6 Million	-560,633 Reduced 13.01%	3,747,549 $135 Million
Q2 2019 Aug 14, 2019	SELL	$36.98 - $41.52 $55.4 Million - $62.3 Million	-1,499,345 Reduced 25.82%	4,308,182 $187 Million
Q1 2019 May 15, 2019	BUY	$37.5 - $41.2 $9.89 Million - $10.9 Million	263,649 Added 4.76%	5,807,527 $247 Million
Q4 2018 Feb 14, 2019	SELL	$38.47 - $43.86 $25.8 Million - $29.4 Million	-671,399 Reduced 10.8%	5,543,878 $242 Million
Q3 2018 Nov 14, 2018	BUY	$34.47 - $41.81 $19.7 Million - $23.9 Million	570,677 Added 10.11%	6,215,277 $274 Million
Q2 2018 Aug 14, 2018	SELL	$32.98 - $35.16 $4.63 Million - $4.94 Million	-140,400 Reduced 2.43%	5,644,600 $205 Million
Q1 2018 May 15, 2018	SELL	$31.91 - $37.02 $8.62 Million - $10 Million	-270,021 Reduced 4.46%	5,785,000 $205 Million
Q4 2017 Feb 14, 2018	SELL	$33.26 - $35.29 $30.2 Million - $32 Million	-907,233 Reduced 13.03%	6,055,021 $219 Million
Q3 2017 Nov 14, 2017	SELL	$31.0 - $34.15 $35.2 Million - $38.7 Million	-1,134,530 Reduced 14.01%	6,962,254 $249 Million
Q2 2017 Aug 14, 2017	BUY	N/A	8,096,784	8,096,784 $272 Million

Others Institutions Holding PFE

# of Institutions

3,260

Shares Held

3.61B

Call Options Held

77.2M

Put Options Held

122M

Vanguard Group Inc Valley Forge, PA

516M
Shares

$13.6 Billion
0.27% of portfolio
Black Rock Inc. New York, NY

424M
Shares

$11.2 Billion
0.27% of portfolio
State Street Corp Boston, MA

290M
Shares

$7.66 Billion
0.35% of portfolio
Wellington Management Group LLP Boston, MA

164M
Shares

$4.32 Billion
0.85% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

130M
Shares

$3.43 Billion
0.73% of portfolio

View Full List

About PFIZER INC

Ticker PFE
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 5,612,349,952
Market Cap $148B
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...

More about PFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.

Account